Adbry shows sustained effectiveness in atopic dermatitis

Leo Pharma has recently shared promising long-term safety and efficacy data for its atopic dermatitis medication, Adbry (tralokinumab-ldrm), underscoring the drug’s capacity to maintain clear or nearly clear skin for up to six years. This data originates from the Phase III ECZTEND study (NCT03587805), where patients on long-term maintenance treatment with Adbry reported substantial improvements.

Specifically, in the study, 92.9% of patients experienced at least a 75% reduction in the Eczema Area and Severity Index (EASI-75) by week 248. Moreover, 66.7% of patients achieved clear or almost clear skin, as evaluated by the Investigator’s Global Assessment (IGA) scale. Importantly, no new safety issues were identified during the study. These findings were shared through a poster presentation at the Fall Clinical Dermatology Conference held in Las Vegas, Nevada from October 24-27.

Adbry received US Food and Drug Administration (FDA) approval in 2021 for treating adults with moderate-to-severe atopic dermatitis. In 2023, this approval was extended to include adolescents aged 12 and older whose condition is inadequately managed with topical prescription therapies or when these therapies are unsuitable. Furthermore, the FDA approved a single-dose autoinjector for Adbry in June 2024.

In financial terms, LEO Pharma reported net sales of DKK 11.4 billion (about $1.7 billion) in 2023, with the success of Adbry being a significant contributor. Looking ahead, GlobalData's consensus forecasts predict that Adbry will generate global sales of $1.3 billion by 2030.

Participants in the open-label ECZTEND study had been previously involved in various monotherapy and combination therapy trials for Adbry. These included the Phase III ECZTRA 1 (NCT03131648) and ECZTRA 2 (NCT03160885) studies focused on Adbry monotherapy, and the Phase III ECZTRA 3 (NCT03363854) study assessing Adbry in combination with topical corticosteroids. Eligibility for ECZTEND was irrespective of the patients' treatment responses in these parent trials or whether they had received Adbry or a placebo.

Adbry specifically targets interleukin-13 (IL-13), a cytokine implicated in the inflammatory processes responsible for the symptoms of atopic dermatitis.